REVIEW

The emerging role of the Ikaros stem cell factor in the neuroendocrine system

Shereen Ezzat\(^1\) and Sylvia L Asa\(^2\)

\(^1\)Department of Medicine and \(^2\)Department of Pathobiology, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada M5G-1X5

(Correspondence should be addressed to S Ezzat who is now at Ontario Cancer Institute, 610 University Avenue, #6-327, Toronto, Ontario, Canada M5G-2M9; Email: shereen.ezzat@utoronto.ca)

Abstract

In this review, we cover the evidence implicating Ikaros as a key factor whose transcriptional actions and chromatin remodeling properties determine the fate of hypothalamic neuroendocrine and pituitary cell population expansion. We propose that the governing mechanisms involved in the regulation and action of Ikaros are of importance during developmental as well as neoplastic transitions.

Journal of Molecular Endocrinology (2008) 41, 45–51

Introduction

The process of anterior pituitary cell development and differentiation follows a highly specific pattern and temporal sequence. Several putative transcription-regulating proteins have been identified in the pituitary and have been implicated as key elements in the definition of cell-specific phenotypes and the regulation of hormone gene expression (Asa & Ezzat 1998, 1999, 2002). Which of the lineage-regulating factors predominates in determining the lineage choice and expansion can be decided not only by the expression and relative concentration of the transcription factor but also by the chromatin accessibility at their cognate sites.

Ikaros was originally described as a transcription factor that binds to regulatory sequences of genes expressed in lymphoid cells (Molnar et al. 1996, Georgopoulos et al. 1997). The single copy gene contains seven exons that can, by alternative splicing, give rise to eight isoforms (Fig. 1) (Hahm et al. 1994, Molnar & Georgopoulos 1994, Sun et al. 1996). All Ikaros isoforms share a common C-terminal domain that contains a transcription activation motif and two zinc finger motifs required for hetero- and homodimerization among the Ik isoforms and for interactions with other proteins (Winandy et al. 1995, Sun et al. 1996, Hahm et al. 1998). The N-terminal region includes a domain with zinc finger motifs critical for DNA binding. Ikaros isoforms differ in the number of N-terminal DNA-binding zinc fingers that differentiate them into members with or without DNA-binding properties (Hahm et al. 1994, Molnar & Georgopoulos 1994). Only Ik1–3 contain the requisite three or more amino (N)-terminal zinc fingers that confer high-affinity binding to an Ikaros-specific core DNA sequence motif in the promoters of target genes (Sun et al. 1996). Dominant-negative (dn) forms of Ikaros lack the DNA-binding domain.

The various isoforms can act either as transcriptional activators or repressors as part of an integral component of a functionally diverse chromatin remodeling network (Molnar et al. 1996). It has become readily evident that the Ikaros system represents an example of a finely tuned system with distinct regulatory functions, particularly during early developmental stages in restricted target tissues.

In the earliest studies, Ikaros expression was identified in the brain and pituitary (Georgopoulos et al. 1992), but this was largely left uninvestigated. Our interest in this gene was precipitated by our identification of abundant expression of Ikaros in the anterior pituitary gland and hypothalamic neurons where we have demonstrated important functions for this factor in the regulation of multiple hormones including proopiomelanocortin (POMC), growth hormone (GH), prolactin (PRL), and GH-releasing hormone (GHRH). We have also identified a role for Ikaros in modulating neuroendocrine cell growth and survival functions (Ezzat et al. 2003, 2006b).
In this review, we cover the evidence implicating Ikaros as a key factor whose transcriptional actions and chromatin-remodeling properties direct hypothalamic neuroendocrine and pituitary cell population expansion during the development. We propose that the governing mechanisms involved in the regulation and action of Ikaros are of importance during developmental as well as neoplastic transitions.

The importance of Ikaros in hematopoietic stem cell commitment

Gene-targeting experiments have firmly established that nuclear factors encoded by the Ikaros gene are essential for normal lymphoid development (Cortes et al. 1999). Mice homozygous for a null mutation in Ikaros display deficient B- and T-cell differentiation (Wang et al. 1996, Winandy et al. 1999), whereas those homozygous for a dn mutant form of Ikaros lack all lymphocytes (Georgopoulos et al. 1994). The more severe phenotype of the dn Ik mutant suggested the presence of Ikaros homologs, leading to the identification of the related factors Aiolos (Morgan et al. 1997), Helios (Hahm et al. 1998, Kelley et al. 1998), and Eos (Cortes et al. 1999). In addition to its role in differentiation, Ikaros plays an important role in regulating cell proliferation. Ik+/− mice exhibit hyperactive T-cell receptor-mediated proliferative responses and eventually develop leukemias and lymphomas (Winandy et al. 1995, Avitahl et al. 1999). Animals heterozygous for the dn Ik-6 that lacks the DNA-binding domain develop T-cell lymphoproliferative disorders similar to human T-lymphoblastic leukemia or lymphoma, presumably as a result of inactivation of the normal allele (Winandy et al. 1995). Thus, Ikaros appears to be an essential regulator of early lymphocyte differentiation as well as differentiated cell expansion.

The essential role of Ikaros in anterior pituitary cell growth and survival

Ikaros directs anterior pituitary cell expansion

Our studies focused on detailed characterization of the striking neuroendocrine phenotypes of the Ikaros-deficient mouse model. In particular, the homozygous null mice exhibit a profound dwarf phenotype with nearly 95% mortality by 6 weeks of age (Ezzat et al. 2005a). The heterozygous Ik+/− mice survive for 4–5 months and subsequently develop lymphoproliferative disorders with leukemic or atypical lymphoid infiltrates of several tissues.
Although these animals were thought to develop infection with sepsis, complete autopsy examinations of our mice have not identified evidence of infection or sepsis. Rather, they show wasting with features of a profound metabolic/endocrine syndrome. Tissue and blood cultures were found to be negative. These animals have normal myeloid marrow elements, and there is no evidence of a neutrophilic response to infection. Moreover, reconstitution of Ikaros-deficient animals after birth with wild-type marrow demonstrated no measurable impact on size and overall health attributable to successful lymphocyte repopulation, supporting the hypothesis of an endocrine/metabolic basis for the phenotype (Ezzat et al. 2005a). These experiments provided compelling evidence for a lymphocyte-independent role for Ikaros in governing neuroendocrine system development.

**Ikaros modulates pituitary cell survival**

Animals heterozygous for dn forms of Ikaros (isoforms that lack the DNA-binding domain) develop T-cell disorders similar to human T-lymphoblastic leukemia or lymphoma, presumably by inactivation of the normal Ikaros allele (Wimandy et al. 1995). Over-expression of a dn non-DNA-binding isoform Ik6 has been identified in a third of cases of B-cell acute leukemias (Nakase et al. 2000). Ikaros mutant mice display a decrease in expression of flk-2 and c-kit receptors, which may in part contribute to the early lymphopoietic phenotypes manifested in the absence of Ikaros (Nichogiannopoulos et al. 1999).

Having identified that Ikaros is expressed in the normal pituitary, we then examined its expression in neoplastic tissues. We detected Ik1 and Ik2/3 protein isoforms in human and mouse pituitary nuclear fractions (Ezzat et al. 2003). We also identified Ik6 expression in nearly 50% of human pituitary adenomas (Ezzat et al. 2003). Forced expression of this dn form of Ikaros resulted in histone 3 acetylation with the activation of the Bcl-XL promoter (Ezzat et al. 2006b). Parallel induction of the endogenous gene resulted in enhanced pituitary cell survival and evasion from apoptotic signals.

**Ikaros promotes anterior pituitary cell differentiation through cellular lipids**

To further determine the mechanisms of action of Ikaros in pituitary cell growth and differentiation, we used a cDNA microarray to uncover mediators of cholesterol uptake including the low-density lipoprotein receptor (LDL-R) and sterol regulatory element-binding protein 2 as targets of Ik action (Loeper et al. 2008). We showed that Ikaros regulates the LDL-R to alter metabolism in pituitary corticotroph cells. The DNA-binding Ikaros isoform, Ik1, binds and enhances activity of the LDL-R promoter. Ik1 decreases methylation and increases acetylation of histone 3 lysine 9 at the LDL-R promoter (Loeper et al. 2008). Confocal microscopy and quantitative fluorometry demonstrated enhanced LDL endocytosis in Ik1-transfected cells that exhibited abundant endoplasmic reticulum, large Golgi complexes, and prominent secretory granule formation, consistent with more robust cholesterol incorporation into functionally relevant membrane-rich organelles. Consistent with these data, LDL-R−/− mice, like Iκ−/− mice, have decreased circulating levels of adrenocorticotropic hormone (Loeper et al. 2008). These findings expand the repertoire of Ikaros actions to include regulation of the cholesterol uptake metabolic pathway. This novel link between tumor suppression and differentiation provides a relationship between cellular metabolism and cancer, and has therapeutic implications for lipid-modifying drugs in Ikaros-associated disorders.

**Ikaros drives corticomelanotroph population expansion**

To quantify the in vivo effects of Ikaros on hypothalamic–pituitary development, we examined in detail the effects of disruption of Ikaros on hypothalamic–pituitary architecture, cell number and area by quantitative morphometric analyses, proliferation rates, and apoptotic indices. Morphologic and morphometric examination of these animals reveals pituitary hypoplasia and dysgenesis in Iκ-null mice. During fetal development, there is delayed progression of pituitary development with small, but architecturally normal pituitaries compared with wild-type littermates that have normal pituitary development (Shewchuk et al. 1999). After birth, the Iκ-null mice continue to exhibit a marked reduction in pituitary mass. They have normal cytodifferentiation with the presence of GH-positive somatotrophs, PRL-positive lactotrophs, adrenocorticotrophin (ACTH)-positive corticotrophs, and thyrotrophin (TSH)-reactive thyrotrophs and gonadotrophs containing follicle-stimulating hormone and luteinizing hormone. However, there are marked reductions in the number of adenohypophysial cells, most strikingly involving the ACTH- and GH-producing populations. The pituitaries of homozygote mice exhibited a striking reduction of melanocorticophores, which was most marked in the intermediate lobe. The heterozygote and homozygote animals showed no evidence of the classical expansion of the melanocorticophores that normally proliferate to occupy the entire intermediate lobe.

To specifically examine the functional consequences of disrupted Ikaros signaling on pituitary corticomelanotroph development, we compared the hormonal and developmental profiles of Iκ-null mice with their
heterozygote and wild-type littermates (Ezzat et al. 2005a). Homozygote Ik-null mice demonstrated the lowest levels of ACTH in the systemic circulation. Levels of the POMC-derived melanocyte-stimulating hormone were also reduced in heterozygote but more strikingly in Ik-null mice. The functional consequences of a diminished population of POMC-producing corticomedianotroph cells were most evident in homzygote mice. Consistent with the trophic functions of ACTH on adrenocortical development and function, Ik-null mice display reduced circulating corticosterone levels compared with heterozygote and wild-type littermates. These changes were also reflected by the reduction of adrenal gland size with striking loss of adrenocortical mass, especially in homozygous Ik-deficient mice.

To examine the possibility that the diminished POMC production and adrenocortical insufficiency in Ikaros-deficient animals may be mediated through altered cytokine production by a dysregulated lymphocyte population, we examined the impact of wild-type bone marrow reconstitution on the endocrine phenotype. Five weeks after adoptive bone marrow transfer in neonatal mouse, the proportion of splenic CD4+ and CD8+ T-cells in the homozygous Ik-null recipients of Ik wild-type syngenic bone marrow was significantly restored compared with vehicle-treated controls. Despite successful reconstitution with normal lymphocytes, the phenotype of homzygote Ik-null animals was unchanged with persistently small pituitaries and reduction in POMC expression that was indistinguishable from vehicle-treated age-matched homzygote animals. Moreover, neither heterozygote nor homozygote Ik-deficient animals demonstrated a significant change in serum corticosterone levels following reconstitution with wild-type lymphocytes. These data provide evidence for a direct role of Ikaros in pituitary corticomedianotroph development and function independent of its influence on lymphopoiesis.

Recognizing that Ikaros mutant mice display adrenocortical insufficiency, we examined the impact of systemic hormone replacement on growth and survival of the Ik-null mouse. Glucocorticoid hormone treatment compared with vehicle alone resulted in significant weight increase in Ik-null mice; the effect was also present, but less evident, in heterozygote animals. By comparison, the same treatment displayed no significant impact on the growth of wild-type animals.

Overall, homozygote Ik-null mice display diminished life expectancy with nearly 5% mortality at birth, 40% by 3 weeks of age, and 95% by 6 weeks of age. Given the recognized functions of Ikaros on immune cell development and function, we performed complete organ surveys in search of opportunistic infections or malignancy. However, we found no evidence of either of these conditions to explain the observed mortality at these stages of development. Moreover, hormone treatment with glucocorticoids resulted in improved survival. In particular, Ik-null mice treated with the adrenocortical hormone demonstrated 100% survival beyond 6 weeks of age. For comparison, none of the vehicle-treated homozygote mice survived beyond the same time point.

Ikaros binds and activates the POMC gene

To determine the mechanism of Ikaros action responsible for the corticotroph insufficient phenotype, we analyzed the rat POMC promoter at five potential Ik-binding sites within the −543 bp promoter (Ezzat et al. 2005a). The importance of these putative Ikars-binding sites was examined by electromobility shift assay and luciferase reporter assays. Two of the three sites that formed specific super-shifted complexes (fragment I (−451/−420) and fragment II (−163/−137)) were identified to be functionally significant as determined through mutational analyses and co-transfection studies (Ezzat et al. 2005a). These Ikaros-binding sites in the POMC promoter are within close proximity (~70 bp) upstream and downstream of the recently identified Tpit/Pitx1 regulatory element (Lamloët et al. 2001). The T-box factor Tpit is restricted to POMC-expressing corticomedianotroph pituitary cells (Lamloët et al. 2001). It activates POMC transcription in cooperation with contiguously bound Pitx1 by recruiting the SRC/p160 co-activators (Maira et al. 2003). Given the critical role of Ikaros in nuclear dimerization, the potential for physical interaction between Ikaros and Tpit needs to be specifically examined. Nevertheless, forced Ikaros expression, but not (dn) Ik6, results in induction of the endogenous POMC gene at the mRNA and protein levels (Ezzat et al. 2005a).

Hypothalamic Ikaros actions

Ikaros directs somatotroph expansion through hypothalamic GHRH regulation

Ikaros-deficient animals display a dwarf phenotype with body weight reaching only ~50% of their wild-type littermates. This dwarfism is associated with diminished GH secretion as evidenced by a reduction of the GH-target growth factor insulin-like growth factor-I (IGF-I) by >50% in homzygote animals. The Ikaros heterozygote-deficient animals display near normal somatic growth with more modest (~12%) reductions in IGF-I levels compared with wild-type mice. Healthy homozygote mice had the same body proportions as those of heterozygote and wild-type mice. At autopsy, internal organs were proportionally equivalent across the genotypes with the exception of the contracted pituitary and adrenal glands of homzygote mice. These features of GH deficiency are not a result of nonspecific
generalized pituitary dysgenesis, since the animals have normal or slightly elevated circulating levels of TSH and PRL. Although these animals exhibit glucocorticoid deficiency that could account for GH insufficiency, glucocorticoid replacement that significantly improved PRL. Although these animals exhibit glucocorticoid normal or slightly elevated circulating levels of TSH and generalized pituitary dysgenesis, since the animals have normal or slightly elevated circulating levels of TSH and PRL. Although these animals exhibit glucocorticoid deficiency that could account for GH insufficiency, glucocorticoid replacement that significantly improved PRL.

The changes of proportionate postnatal dwarfism are indicative of GH deficiency in homozygous Ik-null mice. Again, to exclude the possibility of a secondary response to immunodeficiency, we performed bone marrow reconstitution studies and showed that hematopoietic replacement does not alter IGF-I levels and restore normal growth. We carried out administration of exogenous GH with a response of circulating IGF-I levels and body weight reflecting somatic growth (Ezzat et al. 2005a).

The pituitary somatotroph population displayed quantitative differences across the Ikaros genotypes during early postnatal development. Somatotrophs were present in approximately the same proportion of cells in all genotypes, but the glands are smaller in heterozygotes than in wild-type mice and are even smaller in homozygotes. The intensity of GH reactivity was also reduced in homozygote mice. GH positivity persists in the intermediate lobe of the lateral wings likely attributable to the lack of melanocorticotrope expansion that normally replaces intermediate lobe somatotrophs during development. Other cell types were not measurably affected; the number and area of immunoreactive thyrotrhops and gonadotrophs were not disproportionately different from those of wild-type littermates (Ezzat et al. 2006a).

To examine the regulation of GH by Ikaros, we examined pituitary mammosomatotroph GH4 cells that express abundant Ikaros. We found that Ikaros reciprocally regulates the GH and PRL genes (Ezzat et al. 2005b). In contrast to the expected results, we documented that wild-type Ikaros (Ik1) inhibits GH mRNA and protein expression while stimulating PRL mRNA and protein levels. Ikaros does not bind directly to the proximal (−360) GH promoter. Instead, Ikaros significantly abrogates the eect of the histone deacetylation inhibitor trichostatin A on this promoter. Ikaros selectively deacetylates histone 3 residues on the proximal transfected or endogenous GH promoter and limits access of the Pit1 activator. By contrast, Ikaros acetylates histone 3 on the proximal PRL promoter and facilitates Pit1 binding to this region in the same cells (Ezzat et al. 2005b). These data provide evidence for Ikaros-mediated histone acetylation and chromatin remodeling in the selective regulation of pituitary GH and PRL hormone gene expression in mammosomatotroph cells.

This paradoxical result did not explain the dwarf phenotype of the Ik-null mice, and therefore another explanation for GH deficiency was sought in the hypothalamus. Abundant levels of Ikaros expression were identified in the hypothalamus of wild-type littermates. This staining was localized predominantly within the ventral hypothalamus and was colocalized with GHRH in hypothalamic neurons (Ezzat et al. 2006a). The number of positive cells reaches a maximum at embryonic day (e)18 and shows a reduction in newborn mice; only scattered cells are positive in the adult brain. Ik-null mice showed a striking lack of hypothalamic GHRH. Over-expression of Ikaros enhanced GHRH promoter activity and induced endogenous GHRH gene expression, proving that there is a critical role of Ikaros in the functional regulation of GHRH (Ezzat et al. 2006a). These data unmask a wider role for Ikaros in the neuroendocrine system, highlighting a critical contribution to the development of the hypothalamic–pituitary somatotrophic axis.

Higher central nervous system Ikaros actions

Ikaros transcription factors are also expressed in the brain with predominance in the developing striatum where the putative binding site (5’-GGGA-3’) in the promoter of the mouse and rat enkephalin genes is readily identified (Dobi et al. 1997). One study focusing on the relevance of Ik to the enkephalinergic system (Agoston et al. 2007) concluded that Ik is co-expressed with enkephalin mRNA and may act as a positive regulator of enkephalinergic specification in the developing striatum. While enkephalin is one of several striatal co-transmitters, expressed by a subset of medium spiny neurons (MSNs), there are many others, including gamma-aminobutyric acid (GABA), substance P, and dopamine D1 and D2 receptors (reviewed in (Holt et al. 1997)). We found Ik in precursor cells of several neurostriatal compartments, suggesting that it may play a role as a general maturation factor for MSNs.

With these neuro-localization studies in mind, we proceeded to systematically examine the impact of loss of Ikaros on neurostriatal-mediated functions. We performed a battery of standardized neurobehavioral tests including the elevated plus maze (a measure of anxiety-like behavior), the acoustic startle response and pre-pulse inhibition tests (measures of motor and autonomic reaction), the pinch test (a measure of catalepsy), and contextual fear conditioning (measures of learning and emotion). None of these behavioral functions were significantly altered in Ik-null mice, however, it was specifically in the Porsolt’s forced swim test (a measure of depression-like behavior), where we found Ik−/− mice spending significantly less time in immobility than their Ik+/+ littermates (Kiehl et al. 2008). This phenotype is consistent with
reduced behavioral despair. These findings suggest that Ikaros-mediated neuro striatal cytodifferentiative functions impose significant and selective impact on depressive behavior (Kiehl et al. 2008). The neuro-chemical Ikaros targets involved in mediating these functions will undoubtedly provide novel pharmacologic opportunities for the treatment of psychoaffec- tive disorders.

Conclusions

The identification of Ikaros as a transcriptional regulator of the POMC gene and consequently the ACTH–adrenal axis, its epigenetic control of the GH/PRL axis, and the exciting new finding of Ikaros in selected hypothalamic and striatal neurons, raises new questions about the pleiotropic neuroendocrine functions of this zinc finger protein (Fig. 2). The established functions of Ikaros as a mediator of early and late hematopoietic cell differentiation and proliferation provide further insights into the role of Ikaros as an integrator of endocrine, immune, and neurobehavioral functions. The studies reviewed here indicate that Ikaros can influence hypothalamic–pituitary cell development, differentiation, proliferation, and/or transformation, and provide evidence that these effects are mediated through overlapping and redundant cellular and nuclear targets. The balance between Ikaros and its dn Ik6 isoform appears to regulate multiple promoters through histone acetylation and methylation-dependent mechanisms. The net influence of these interactions is ultimately expected to favor a chromatin environment that permits recruitment of an activating or repressing complex essential for gene-specific control.
Declaration of interest

The authors have nothing to disclose. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


Winandy S, Wu L, Wang JH & Georgopoulos K 1999 Pre-T cell receptor (TCR) and TCR-controlled checkpoints in T cell differentiation are set by Ikaros. Journal of Experimental Medicine 190 1039–1048.

Received in final form 6 May 2008
Accepted 29 May 2008
Made available online as an Accepted Preprint 29 May 2008